FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021422677> ?p ?o ?g. }

• W2021422677 abstract "Several clinical studies reported the efficacy of the long-acting SRIH analog, octreotide (Octreotide, Sandoz) in the treatment of acromegaly. Recently, another SRIH analog (BIM 23014, Ipsen Biotech) was shown to decrease plasma GH levels in acromegalic patients. The recent availability of a long-acting formulation of BIM 23014 [slow release (SR) lanreotide] could avoid the inconveniences associated with either repeated sc injections or continuous sc infusions. In this study, we compared the clinical and biochemical efficacies of both drugs in a cohort of 19 acromegalic patients, considered initially as responsive to octreotide and sequentially treated with octreotide (3 sc injections of 100-200 micrograms/day) for 12 months and with SR lanreotide (30 mg, im, every 10 or 14 days) for 6 months. Before octreotide treatment, baseline plasma GH (mean +/- SE of 8 hourly samplings) was 29.0 +/- 10.0 micrograms/L and was lowered to 3.2 +/- .2 micrograms/L during the first 7 h after the first 100-micrograms sc octreotide administration. After 12 months of treatment with octreotide, 14 of 19 patients (74%) were considered normalized, as their mean individual GH profiles and insulin-like growth factor-I (IGF-I) values were within the normal range. After octreotide withdrawal for 1 week, plasma GH and IGF-I levels rose to 18.3 +/- 4.8 and 4.1 +/- 0.4 U/mL, respectively. The first 30-mg SR lanreotide im injection produced an acute suppression of plasma GH levels (mean GH value during the 7 h after the injection, 3.0 +/- 0.4 micrograms/L), not different from results previously observed after the first octreotide injection. After 3 months of treatment with 30 mg SR lanreotide every 14 days, normalization of baseline GH and IGF1 levels was achieved in 6 of 19 patients. Ten patients, who did not achieve normal GH levels, subsequently received a 30-mg SR lanreotide injection every 10 days. Among them, normalization of GH and IGF-I levels occurred in 7 of 10 patients after 3 months of such a regimen. After 6 months of SR lanreotide treatment, 13 of 19 patients (68%) were considered normalized, with mean GH and IGF-I values, respectively, of 3.1 +/- 0.4 micrograms/L and 1.5 +/- 0.1 U/mL. The overall tolerance of both drugs (glucose homeostasis and gallstone formation) was similar.(ABSTRACT TRUNCATED AT 400 WORDS)" @default.
• W2021422677 created "2016-06-24" @default.
• W2021422677 creator A5028728211 @default.
• W2021422677 creator A5029716255 @default.
• W2021422677 creator A5051337417 @default.
• W2021422677 creator A5059116702 @default.
• W2021422677 creator A5064696388 @default.
• W2021422677 creator A5066125288 @default.
• W2021422677 creator A5067519967 @default.
• W2021422677 creator A5079834835 @default.
• W2021422677 date "1994-07-01" @default.
• W2021422677 modified "2023-09-26" @default.
• W2021422677 title "Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide." @default.
• W2021422677 cites W1968781826 @default.
• W2021422677 cites W1970252755 @default.
• W2021422677 cites W1991986331 @default.
• W2021422677 cites W1993348257 @default.
• W2021422677 cites W2005614064 @default.
• W2021422677 cites W2012615488 @default.
• W2021422677 cites W2021353890 @default.
• W2021422677 cites W2025997743 @default.
• W2021422677 cites W2090065340 @default.
• W2021422677 cites W2092766569 @default.
• W2021422677 cites W2120633602 @default.
• W2021422677 cites W2134508147 @default.
• W2021422677 cites W2145493248 @default.
• W2021422677 cites W2145509053 @default.
• W2021422677 cites W2159248680 @default.
• W2021422677 cites W2339145711 @default.
• W2021422677 cites W2464162544 @default.
• W2021422677 doi "https://doi.org/10.1210/jcem.79.1.8027218" @default.
• W2021422677 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8027218" @default.
• W2021422677 hasPublicationYear "1994" @default.
• W2021422677 type Work @default.
• W2021422677 sameAs 2021422677 @default.
• W2021422677 citedByCount "51" @default.
• W2021422677 countsByYear W20214226772017 @default.
• W2021422677 countsByYear W20214226772018 @default.
• W2021422677 countsByYear W20214226772021 @default.
• W2021422677 countsByYear W20214226772022 @default.
• W2021422677 crossrefType "journal-article" @default.
• W2021422677 hasAuthorship W2021422677A5028728211 @default.
• W2021422677 hasAuthorship W2021422677A5029716255 @default.
• W2021422677 hasAuthorship W2021422677A5051337417 @default.
• W2021422677 hasAuthorship W2021422677A5059116702 @default.
• W2021422677 hasAuthorship W2021422677A5064696388 @default.
• W2021422677 hasAuthorship W2021422677A5066125288 @default.
• W2021422677 hasAuthorship W2021422677A5067519967 @default.
• W2021422677 hasAuthorship W2021422677A5079834835 @default.
• W2021422677 hasConcept C126322002 @default.
• W2021422677 hasConcept C134018914 @default.
• W2021422677 hasConcept C2776297358 @default.
• W2021422677 hasConcept C2777433750 @default.
• W2021422677 hasConcept C2779609023 @default.
• W2021422677 hasConcept C2781025020 @default.
• W2021422677 hasConcept C2984496839 @default.
• W2021422677 hasConcept C71315377 @default.
• W2021422677 hasConcept C71924100 @default.
• W2021422677 hasConceptScore W2021422677C126322002 @default.
• W2021422677 hasConceptScore W2021422677C134018914 @default.
• W2021422677 hasConceptScore W2021422677C2776297358 @default.
• W2021422677 hasConceptScore W2021422677C2777433750 @default.
• W2021422677 hasConceptScore W2021422677C2779609023 @default.
• W2021422677 hasConceptScore W2021422677C2781025020 @default.
• W2021422677 hasConceptScore W2021422677C2984496839 @default.
• W2021422677 hasConceptScore W2021422677C71315377 @default.
• W2021422677 hasConceptScore W2021422677C71924100 @default.
• W2021422677 hasLocation W20214226771 @default.
• W2021422677 hasLocation W20214226772 @default.
• W2021422677 hasOpenAccess W2021422677 @default.
• W2021422677 hasPrimaryLocation W20214226771 @default.
• W2021422677 hasRelatedWork W1969479791 @default.
• W2021422677 hasRelatedWork W1985225714 @default.
• W2021422677 hasRelatedWork W1986534518 @default.
• W2021422677 hasRelatedWork W1992276642 @default.
• W2021422677 hasRelatedWork W2004517907 @default.
• W2021422677 hasRelatedWork W2007123753 @default.
• W2021422677 hasRelatedWork W2021669190 @default.
• W2021422677 hasRelatedWork W2093971360 @default.
• W2021422677 hasRelatedWork W2141667495 @default.
• W2021422677 hasRelatedWork W2014450888 @default.
• W2021422677 isParatext "false" @default.
• W2021422677 isRetracted "false" @default.
• W2021422677 magId "2021422677" @default.
• W2021422677 workType "article" @default.